Feature | June 12, 2015

Follow-up PET/CT Altering Patient Management for Non-Hodgkin Lymphoma

Molecular imaging found to be 95 percent sensitive in catching early recurrence

non-Hodgkins lymphoma, PET/CT, recurrence, SNMMI 2015

June 12, 2015 - Post-treatment surveillance with molecular imaging could mean the early start of a new, life-saving treatment for non-Hodgkin lymphoma (NHL), said researchers at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

NHL - a potentially devastating cancer of the blood and immune system - is the fifth most prevalent cancer in America, according to lead author Mehdi Taghipour, M.D., a research fellow from the department of radiology at the Johns Hopkins Medical Institutions in Baltimore, Maryland. A majority of NHL patients are treated successfully with frontline chemotherapy, but about 20-50 percent of patients with aggressive lymphoma are expected to relapse within three years. Functional and structural imaging with a combination of positron emission tomography and computed tomography (PET/CT) has the potential to catch a relapse in its earliest stages.

"A permanent cure may still be achieved using salvage chemotherapy, but early diagnosis of a relapse is essential," said Taghipour. "PET/CT imaging is superior to conventional imaging for NHL, but the role of post-treatment PET/CT has been controversial. Our study proves that 39 percent of follow-up PET/CT scans added clinical value, which represents a significant improvement in NHL patient care."

The study included a collective 560 PET/CT scans from 204 patients. Imaging was performed six months or more after completion of primary therapy. Researchers assessed the value of follow-up PET/CT by conducting statistical analysis to determine changes in patient management and evaluated the accuracy of these scans comparing to either histopathology or additional six-month follow-up.

Results of the study showed that the sensitivity of PET/CT for detecting relapsed NHL was 95.1 percent. Specificity, or the ability to rule out NHL, was gauged at 90.5 percent. Positive and negative predictive values, which provide insight into the ability of the scan to accurately determine the presence or absence of a disease, were 84.5 percent and 97.1 percent, respectively. Lastly, overall accuracy of follow-up PET/CT with the common imaging agent fluorodeoxyglucose (FDG), which provides a map of cellular metabolic activity, was 92.1 percent.

Follow-up PET/CT led to changes in patient management in 17 percent of scan times, and new treatments were initiated after 15.7 percent of scan times. More than 69 percent of scans were performed without prior clinical suspicion of recurrence, and 30.7 percent of scans were ordered because of suspected disease, More than 22 percent of follow-up scans showed suspected disease when there was no clinical suspicion for disease recurrence, and presence of disease was ruled out in 17.4 percent of scans while the treating physician suspected recurrence prior to the scan.

An estimated 71,850 people will be diagnosed with NHL and 19,790 people will die of the disease this year, according to 2015 statistics from the American Cancer Society.

For more information: www.snmmi.org

Related Content

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Videos | Interventional Radiology | January 11, 2019
Julius Chapiro, M.D., research faculty member and an...
AI Approach Outperformed Human Experts in Identifying Cervical Precancer
News | Digital Pathology | January 10, 2019
January 10, 2019 — A research team led by investigators from the National Institutes of Health and Global Good has de
Heart Attack, Stroke Risks Increase Leading Up to Cancer Diagnosis
News | Cardio-oncology | December 21, 2018
Older adults with cancer are more likely to have had a heart attack or stroke in the months prior to their cancer...
Opto-Acoustic Imaging Helps Differentiate Breast Cancer Molecular Subtypes
News | Ultrasound Women's Health | December 20, 2018
Seno Medical Instruments Inc. (Seno Medical) reported results of a study demonstrating that morphologic and functional...
Videos | SPECT-CT | December 12, 2018
This is a walk around of the new Spectrum Dynamics Veriton SPECT-CT nuclear imaging system introduced at the 2018 ...
YITU Releases AI-Based Cancer Screening Solutions at RSNA 2018
News | Artificial Intelligence | December 06, 2018
Chinese artificial intelligence (AI) healthcare company YITU healthcare released two brand-new products, Intelligent...
Spectrum Dynamics Sues GE for Theft, Misappropriation of Trade Secrets and Unfair Competition
News | SPECT Imaging | December 06, 2018
Single-photon emission computed tomography (SPECT) cardiac imaging company Spectrum Dynamics filed a lawsuit Dec. 6,...
Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET
Technology | PET Imaging | December 05, 2018
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...